Header Logo

Connection

MICHAEL HOLLIDAY to Class I Phosphatidylinositol 3-Kinases

Back to Details
This is a "connection" page, showing publications MICHAEL HOLLIDAY has written about Class I Phosphatidylinositol 3-Kinases.
MICHAEL HOLLIDAY
Connection Strength
0.051
Class I Phosphatidylinositol 3-Kinases
  1. Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Ka Inhibitor That Decouples Antitumor Activity from Hyperinsulinemia. Cancer Discov. 2024 Feb 08; 14(2):240-257.
    View in: PubMed
    Score: 0.051
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.